Navigation Links
Biotech Begins Year on a Quiet, but Optimistic Note
Date:2/2/2011

SAN FRANCISCO, Feb. 2, 2011 /PRNewswire/ -- The biotech industry opened the New Year quietly with the Burrill Biotech Select Index up marginally for January at 0.3 percent. Meanwhile, the capital markets recorded their strongest January in years. The Dow Jones Industrial average closed the month with a 2.7 percent gain and the Nasdaq Composite index closed up 1.8 percent.

"Although not yet reflected in biotech's performance on the capital markets, the mood at the annual J.P. Morgan Healthcare Conference in San Francisco early January was upbeat reflecting the fact that many biotech and pharma CEOs believe that 2011 will be a good one for them," said G. Steven Burrill, CEO, Burrill & Company, a diversified global financial services firm focused on the life sciences industry.

"I believe we will see an increase in M&A activity in biotech land as companies position themselves for growth this year. It was clear that pharma executives were checking out promising companies to bolster their product pipelines...and several large biotechs, sitting on plenty of cash, made their intentions known that they are looking to acquire assets. Amgen, for example, pulled the trigger on a $1 billion deal late January to acquire BioVex, the creator of a late-stage cancer vaccine that has shown encouraging results in treating solid tumors," noted Burrill.

"We will also see in the next couple of weeks a final resolution to Sanofi Aventis' bid to acquire Genzyme," commented Burrill. "In addition, at the J.P. Morgan event several big pharma companies re-emphasized the growing importance of emerging markets to strengthen their bottom line," added Burrill. "It has been well documented that the global pharmaceutical market is poised to grow by as much as 7 percent this year and emerging markets will be a big part of that growth as more government spending and broader access to health care in developing economies drive demand."

The Burrill Personalized Index climbed almost 3 percent in January. "As we describe in our upcoming 25th anniversary issue of our annual report Biotech 2011, this sector will be hot," commented Burrill. "There is no doubt that we are moving to a world that embraces not only the possibility of using a person's genetic information to identify their risks for disease but also individualized strategies for prevention or treatment and companies in the healthcare sector are positioning themselves for this trend. As a result, we are seeing plenty of deals as companies orient their R&D strategies in the personalized medicine space."

Market Cap

According to the January issue of the Burrill Report, (www.burrillreport.com) the biotech industry's collective market cap was $378 billion, up 1.5 percent for the month.


'/>"/>
SOURCE Burrill & Company
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
2. Yongye Biotechnology International Retains CCG Investor Relations
3. ThirdBiotech Announces Kemeta as Newest Sponsor
4. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
5. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
6. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
7. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
8. China Kangtai Cactus Biotech Announces Record Second Quarter Results
9. Yongye Biotechnology International Announces Second Quarter Results
10. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is ... and 8th June 2018 in San Francisco, CA. The Summit brings together current and ... distinguished CEOs, board directors and government officials from around the world to address key ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published in ... and fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched ... , After comparing the results from the fresh and frozen transfer cohorts, the ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert ... a media edge server, the M820, which features the company,s hybrid ... software provided by Tera Probe, Inc., will be showcased during the ... the NAB show at the Las Vegas ... ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
Breaking Biology News(10 mins):